SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

11 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

10 6 2024 10:49:02 提供 Nasdaq GlobeNewswire

Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

06 6 2024 13:56:09 提供 Nasdaq GlobeNewswire

Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company

30 5 2024 12:19:34 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index

24 5 2024 12:40:58 提供 Nasdaq GlobeNewswire

Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company

24 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®

14 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering

25 4 2024 15:01:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces $15 Million Registered Direct Offering

24 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses

16 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool

09 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

27 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

21 3 2024 08:30:29 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

20 3 2024 10:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®

20 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

19 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

18 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

15 3 2024 13:45:35 提供 Nasdaq GlobeNewswire

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement

15 3 2024 08:00:00 提供 Nasdaq GlobeNewswire